Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059530 | 0.81 | CYP3A4 (0.54) | ALDH1A1GAAMAPTL3MBTL1POLB | |
| SCHEMBL12551767 | 0.78 | TAAR1 (0.43) | ALDH1A1GAAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL28341702 | 0.78 | NOTUM (0.43) | ALDH1A1GAAMAPTL3MBTL1POLB | |
| SCHEMBL28773420 | 0.77 | HSD17B10 (0.41) | ALDH1A1GAAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL12396791 | 0.77 | CYP3A4 (0.49) | ALDH1A1SMN1; SMN2KDM4EHSD17B10CYP3A4 | |
| SCHEMBL29606534 | 0.77 | HSD17B10 (0.41) | ALDH1A1GAAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL12089620 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1GAAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4061805 | 0.76 | PDE4A (0.47) | ALDH1A1GAAMAPTSMN1; SMN2KDM4E | |
| SCHEMBL14850042 | 0.76 | PKM (0.41) | ALDH1A1GAAL3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL4056315 | 0.74 | TAAR1 (0.43) | ALDH1A1GAAMAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | ALDH1A1 948/4885GAA 1194/4885MAPT 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.